| Ytd | -3.25% | |
| 1y | -19.05% |
| Open | 1.22 | Prev Close | 1.21 | Low | 1.17 | High | 1.23 | Mkt Cap | 107.34M |
| Vol | 904.58K | Avg Vol | 480.20K | EPS | -0.36 | P/E | N/A | Forward P/E | -2.11 |
| Beta | 3.52 | Short Ratio | 12.59 | Inst. Own | 10.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.36 | 200-d Avg | 1.28 | 1yr Est | 5.50 |
VANI News
ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.07) per share which beat the analyst c
All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-13
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosi
Vivani Medical NASDAQ: VANI said it is preparing to begin human testing of its semaglutide implant i
ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company
NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic w
ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani"), a clinical-stage biopharmaceutical company de
SALT LAKE CITY--(BUSINESS WIRE)--ClearOne, Inc. (Nasdaq: CLRO) (“ClearOne”) announced today that it
Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (Nasdaq: C
ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or
Vivani CEO Adam Mendelsohn, Ph.D., stated, "HREC approval to initiate SLIM-1 in Australia marks
ALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or
Lake Street analyst Thomas Flaten initiates coverage on Vivani Medical (NASDAQ:VANI) with a Buy r
ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” o
Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under develo
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) Director Gregg Williams purchased 1,587,301 sh
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant increase in
Vivani Medical (NASDAQ: VANI - Get Free Report) and Verrica Pharmaceuticals (NASDAQ: VRCA - Get Free
Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.09) per share which beat the analyst c
Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept da
Vivani Medical (NASDAQ: VANI - Get Free Report) is projected to post its Q4 2025 results before the
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant decrease in
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage bio
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst co
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical
https://d1io3yog0oux5.cloudfront.net/_8b0e72ba9731939ad4ef3d445345826e/vivanimedical/db/2227/20875/p
Cortigent is a leading developer of brain implant devices based on precision neurostimulation techno
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administrationFirs
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.12) per share which missed the analyst
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data sh
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage bio
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which missed the analyst
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma
ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:V
Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatm
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst co
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma
Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight lo
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for w